Patents by Inventor Shigetoshi Kikuchi

Shigetoshi Kikuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NANOPARTICLE, CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING COMPRISING SAME AND ZWITTERIONIC LIGAND COMPOUND
    Publication number: 20220184236
    Abstract: Provided is a novel nanoparticle, a contrast agent for magnetic resonance imaging containing the same, and a zwitterionic ligand compound used in production of the nanoparticle. The contrast agent for MRI of the present invention can be suitably used as a contrast agent for MRI in a medical field. The nanoparticle and the zwitterionic ligand compound of the present invention are applicable to various pharmaceutical compositions and the like, including a contrast agent for MRI, and can be used widely in the fields of pharmaceuticals, biotechnology, and the like, including various diagnosis methods and examination reagents.
    Type: Application
    Filed: December 27, 2019
    Publication date: June 16, 2022
    Inventors: Tsuyoshi Mizutani, Hiroyoshi Yamada, Hiroki Toya, Akihiko Fujikawa, Seiji Yoshimura, Shigetoshi Kikuchi, Daigo Miyajima, Toshiaki Takeuchi, Takuzo Aida, Ichio Aoki
  • Bicyclic nitrogen-containing aromatic heterocyclic amide compound
    Patent number: 9428501
    Abstract: Compounds of formula (I) and salts thereof: wherein the variables are defined herein, are useful for the treatment of breast cancer.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: August 30, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Kei Ohnuki, Hidenori Azami, Yuki Sawada, Takashi Shin, Kazuyuki Kuramoto, Shigetoshi Kikuchi, Tomoyuki Saito, Hisao Hamaguchi, Takeyuki Nagashima
  • BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND
    Publication number: 20150266869
    Abstract: [Problem] A compound which is useful as an agent for treating breast cancer is provided. [Means for Solution] As a result of intensive studies on a compound having a Complex I inhibitory effect and an AMPK activation effect, the present inventors found that a bicyclic nitrogen-containing aromatic heterocyclic amide compounds of the present invention has an excellent Complex I inhibitory effect and the AMPK activation effect, furthermore, has a cell proliferation inhibitory effect with respect to not only human PIK3CA mutation-positive breast cancer cell lines in which MCT4 is not expressed but also human breast cancer cell lines which do not have mutation of PIK3CA in which MCT4 is not expressed, and exhibits an anti-tumor effect in a human PIK3CA mutation-positive breast cancer cell line MDA-MB-453 cell in a cancer-bearing mouse in which the MCT4 is not expressed, thereby completing the present invention.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 24, 2015
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Kei Ohnuki, Hidenori Azami, Yuki Sawada, Takashi Shin, Kazuyuki Kuramoto, Shigetoshi Kikuchi, Tomoyuki Saito, Hisao Hamaguchi, Takeyuki Nagashima
  • Pyrazinecarboxamide compound
    Patent number: 9085540
    Abstract: Compounds of formula (I): in which the variables are defined herein, are useful for the treatment of cancer in patients which express the EGFR T790M mutation.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: July 21, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Takahiro Matsuya, Yutaka Kondoh, Itsuro Shimada, Shigetoshi Kikuchi, Maiko Iida, Kenichi Onda, Hiroki Fukudome, Yukihiro Takemoto, Nobuaki Shindou, Hideki Sakagami, Hisao Hamaguchi
  • PYRAZINECARBOXAMIDE COMPOUND
    Publication number: 20140323463
    Abstract: [Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention.
    Type: Application
    Filed: January 15, 2013
    Publication date: October 30, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Takahiro Matsuya, Yutaka Kondoh, Itsuro Shimada, Shigetoshi Kikuchi, Maiko Iida, Kenichi Onda, Hiroki Fukudome, Yukihiro Takemoto, Nobuaki Shindou, Hideki Sakagami, Hisao Hamaguchi